Estetrol Cotreatment of Androgen Deprivation Therapy in Infiltrating or Metastatic, Castration-sensitive Prostate Cancer: A Randomized, Double-blind, Phase II Trial (PCombi)

BACKGROUND: Androgen deprivation therapy (ADT) for prostate cancer with luteinizing hormone-releasing hormone (LHRH) agonists can be improved. OBJECTIVE: To assess safety, the frequency and severity of hot flushes (HFs), bone health, and antitumor effects of high-dose estetrol (HDE4) when combined w...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Eur Urol Open Sci
Hlavní autoři: Coelingh Bennink, Herjan J.T., van Moorselaar, Jeroen A., Crawford, E. David, Roos, Erik P.M., Somford, Diederik M., Roeleveld, Ton A., de Haan, Tjard D., van Melick, Harm H.E., Reisman, Yacov, Zimmerman, Yvette, van Osta, Gonnie, Krijgh, Jan, Shore, Neal D., Saad, Fred, Schally, Andrew V., Debruyne, Frans M.J.
Médium: Artigo
Jazyk:Inglês
Vydáno: Elsevier 2021
Témata:
Prostate Cancer
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8317802/
https://ncbi.nlm.nih.gov/pubmed/34337526
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.euros.2021.04.005
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky